Can a new pill tame tough eczema? a large trial aims to find out
NCT ID NCT06723080
First seen Jul 27, 2026 · Last updated Jul 28, 2026 · Updated 1 time
Summary
This phase 3 trial tests whether an experimental oral drug called VC005 can reduce eczema symptoms in adults with moderate to severe atopic dermatitis. Participants are randomly assigned to receive either a low or high dose of VC005 or a placebo. The main goal is to see if more people on VC005 achieve at least a 75% improvement in their eczema severity after 16 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- an experimental oral drug called VC005
- What this could lead to
- If successful, VC005 could offer a new treatment option for people with moderate to severe atopic dermatitis.
- What could go wrong
- This is an early-phase 3 trial, so the drug may not prove effective or could have side effects. Placebo comparison helps measure true benefit.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MODERATE-TO-SEVERE ATOPIC DERMATITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Chinese Academy of Medical Sciences Hospital for Skin Diseases
RECRUITINGNanjing, Jiangsu, 210042, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New shot could tame tough eczema by calming overactive immune cells
- New drug aims to calm severe eczema without steroids
- New drug shows promise for severe eczema in toddlers
- Eczema drug nemolizumab put to the vaccine test
- New shot could tame severe eczema in kids
- Real-world dupixent study tracks eczema improvement in 305 canadians